ALAN RUIZ: Open Payments
NPI 1407099484 · DANIELSON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,016 in 57 payments from 15 companies in 2025. Trend: 2023 $819 · 2024 $719 · 2025 $1,016
Food & beverage: $1,016
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $267 |
| Novo Nordisk Inc | 8 | $145 |
| Phathom Pharmaceuticals, Inc. | 6 | $135 |
| Vanda Pharmaceuticals Inc. | 4 | $94 |
| GlaxoSmithKline, LLC. | 3 | $71 |
| Indivior Inc. | 2 | $68 |
| PFIZER INC. | 2 | $44 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 1 | $31 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
Products named: VOQUEZNA, VRAYLAR, FANAPT, UBRELVY, Ozempic, TRELEGY ELLIPTA, SUBLOCADE, NURTEC ODT.
Industry payments across CT — which companies pay providers there.
